In contrast, another study showed that CEPs decreased in responders and increased in nonresponders with multiple myeloma.15 However, they defined CEP as CD34+VEGFR2+CD45−/dim, different from our definition, and their patients received bortezomib and dexamethasone. This evidence concerns the gene CD34 and plasma cell myeloma.